Gilead's remdesivir priced at $2,340 per treatment

Monday, 29. June 2020 13:37

Gilead Sciences Inc. decided to set the price of its drug Remdesivir, made for treating the COVID-19 patients, at $390 per vial for developed countries, the company's Chief Executive Daniel O'Day said in an open letter on Monday.

Given that the average treatment lasts five days, the amount paid per patient would equate to $2,340. O'Day added that Gilead started negotiations with generic manufacturers "to ensure that all countries in the world can provide access to treatment," so the costs in those regions would be "substantially lower."

On June 25, remdesivir was recommended for European Union authorization as a treatment for COVID-19 in patients older than 12 by the European Medicines Agency.

Related Links: Gilead Sciences Inc.
Breaking the News / BU